A phase I trial studying the combination of avutometinib and everolimus has also shown encouraging preliminary efficacy and safety results, with an ORR of 20%, DFS of 90%, and median PFS of 6.35 months in advanced KRAS-mutated NSCLC [90]. Here, KRAS is linked to non-small cell lung carcinoma.